Factors correlated with improvement of endothelial dysfunction during rituximab therapy in patients with rheumatoid arthritis

Biologics: Targets and Therapy

Volumn 7, Issue 1, 2013, Pages 69-75

  Benucci, Maurizio ^a   Saviola, Gianantonio ^b   Manfredi, Mariangela ^a   Sarzi Puttini, Piercarlo ^c   Atzeni, Fabiola ^c  

^a Hospital di S Giovanni di Dio   (Italy)

^b IRCCS   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Endothelial dysfunction; Rheumatoid arthritis; Rituximab

Indexed keywords

C REACTIVE PROTEIN; CD19 ANTIGEN; IMMUNOGLOBULIN M; INTERLEUKIN 8; METHOTREXATE; PREDNISONE; RITUXIMAB;

ADULT; AGED; ARTERY INTIMA PROLIFERATION; ARTICLE; BRACHIAL ARTERY; CAROTID ATHEROSCLEROSIS; CLINICAL ARTICLE; CLINICAL EVALUATION; COMMON CAROTID ARTERY; DISEASE ACTIVITY SCORE; DISEASE MARKER; DRUG TREATMENT FAILURE; ENDOTHELIAL DYSFUNCTION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; MALE; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME; VASODILATATION;

EID: 84875177703     PISSN: 11775475     EISSN: 11775491     Source Type: Journal    
DOI: 10.2147/BTT.S39182     Document Type: Article

References (34)

1. Kremers HM, Crowson CS, Therneau TM, Roger VL, Gabriel SE. High ten-year risk of cardiovascular disease in newly diagnosed rheumatoid arthritis patients: a population-based cohort study. Arthritis Rheum. 2008;58(8):2268-2274.
2. Aviña-Zubieta JA, Choi HK, Sadatsafavi M, Elminan JM, Esdaile JM, Lacaille D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum. 2008;59(12):1690-1697.
3. Solomon DH, Goodson NJ, Katz JN, et al. Patterns of cardiovascular risk in rheumatoid arthritis. Ann Rheum Dis. 2006;65(12):1608-1612.
4. Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman K V, Gabriel SE. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum. 2005;52(3):722-732.
5. Solomon DH, Karlson E W, Rimm EB, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation. 2003;107(9):1303-1307.
6. del Rincón ID, Williams K, Stern M P, Freeman GL, Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum. 2001;44(12):2737-2745.
7. Wolfe F, Michaud K. The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis: a cohort and nested case-control analysis. Arthritis Rheum. 2008;58(9):2612-2621.
8. Del Rincón I, Williams K, Stern M P, Freeman GL, O'Leary DH, Escalante A. Association between carotid atherosclerosis and markers of infammation in rheumatoid arthritis patients and healthy subjects. Arthritis Rheum. 2003;48(7):1833-1840.
9. Goodson NJ, Symmons DP, Scott DG, Bunn D, Lunt M, Silman AJ. Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with infammatory polyarthritis: a ten-year followup study of a primary care-based inception cohort. Arthritis Rheum. 2005;52(8):2293-2299.
10. Van Doornum S, McColl G, Wicks I.P. Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? Arthritis Rheum. 2002;46(4):862-873.
11. Vita JA, Keaney JF Jr. Endothelial function: a barometer for cardiovascular risk? Circulation. 2002;106(6):640-642.
12. Gonzalez-Juanatey C, Testa A, Garcia-Castelo A, et al. HLADRB1 status affects endothelial function in treated patients with rheumatoid arthritis. Am J Med. 2003;114(8):647-652.
13. Gonzalez-Juanatey C, Testa A, Garcia-Castelo A, Garcia-Porrua C, Llorca J, Gonzalez-Gay MA. Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing longterm treatment with anti-tumor necrosis factor alpha antibody. Arthritis Rheum. 2004;51(3):447-450.
14. Cohen SB, Emery P, Greenwald M W, et al; The REFLEX Trial Group. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary effcacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54(9):2793-2806.
15. Keystone E, Emery P, Peterfy CG, et al. Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies. Ann Rheum Dis. 2009;68(2):216-221.
16. Benucci M, Manfredi M, Puttini PC, Atzeni F. Predictive factors of response to rituximab therapy in rheumatoid arthritis: What do we know today? Autoimmun Rev. 2010;9(12):801-803.
17. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classifcation of rheumatoid arthritis. Arthritis Rheum. 1988;31(3):315-324.
18. Ritchie DM, Boyle JA, McInnes JM, et al. Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. QJMed. 1968;37(147):393-406.
19. Fransen J, van Riel PL. The disease activity score and EULAR response criteria. Clin Exp Rheumatol. 2005;23(5 suppl 39):93-95.
20. Ranza R, Marchesoni A, Calori G, et al. The Italian version of the Functional Disability Index of the Health Assessment Questionnaire. A reliable instrument for multicenter studies in rheumatoid arthritis. Clin Exp Rheumatol. 1993;11(2):123-128.
21. Kerekes G, Szekanecz Z, Dér H, et al. Endothelial dysfunction and atherosclerosis in rheumatoid arthritis: a multiparametric analysis using imaging techniques and laboratory markers of infammation and autoimmunity. J Rheumatol. 2008;35(3):398-406.
22. Sellam J, Hendel-Chavez H, Rouanet S, et al. B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label study. Arthritis Rheum. 2011;63(4):933-938.
23. Sarzi-Puttini P, Atzeni F, Gerli R, et al. Cardiac involvement in systemic rheumatic diseases: An update. Autoimmun Rev. 2010;9(12):849-852.
24. Gerli R, Vaudo G, Bocci EB, et al. Functional impairment of arterial wall in primary Sjögren's syndrome: combined action of immunological and infammatory factors. Arthritis Care Res (Hoboken). 2010;62(5): 712-718.
25. Kokkonen H, Söderström I, Rocklöv J, Hallmans G, Lejon K, Rantapää Dahlqvist S. Up-regulation of cytokines and chemokines predates the onset of rheumatoid arthritis. Arthritis Rheum. 2010;62(2):383-391.
26. Atzeni F, Turiel M, Caporali R, et al. The effect of pharmacological therapy on the cardiovascular system of patients with systemic rheumatic diseases. Autoimmun Rev. 2010;9(12):835-839.
27. Kerekes G, Soltész P, Dér H, et al. Effects of rituximab treatment on endothelial dysfunction, carotid atherosclerosis, and lipid profle in rheumatoid arthritis. Clin Rheumatol. 2009;28(6):705-710.
28. Gonzalez-Juanatey C, Llorca J, Vazquez-Rodriguez TR, Diaz-Varela N, Garcia-Quiroga H, Gonzalez-Gay MA. Short-term improvement of endothelial function in rituximab-treated rheumatoid arthritis patients refractory to tumor necrosis factor alpha blocker therapy. Arthritis Rheum. 2008;59(12):1821-1824.
29. Ait-Oufella H, Herbin O, Bouaziz JD, et al. B cell depletion reduces the development of atherosclerosis in mice. Exp Med. 2010;207(8): 1579-1587.
30. Kyaw T, Tay C, Khan A, et al. Conventional B2 B cell depletion ameliorates whereas its adoptive transfer aggravates atherosclerosis. J Immunol. 2010;185(7):4410-4419.
31. Van Leeuwen M, Damoiseaux J, Duijvestijn A, Tervaert JW. The therapeutic potential of targeting B cells and anti-oxLDL antibodies in atherosclerosis. Autoimmun Rev. 2009;9(1):53-57.
32. Tremblay MS, Colley RC, Saunders TJ, Healy GN, Owen N. Physiological and health implications of a sedentary lifestyle. Appl Physiol Nutr Metab. 2010;35(6):725-740.
33. Ait-Oufella H, Taleb S, Mallat Z, Tedgui A. Recent advances on the role of cytokines in atherosclerosis. Arterioscler Thromb Vasc Biol. 2011;31(5):969-979.
34. van Vollenhoven R F, Emery P, Bingham CO 3rd, et al. Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol. 2010;37(3):558-567.